[开放获取]    中国皮肤结核临床诊疗专家共识（2024版）

doi:10.35541/cjd.20230354

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (5): 426-434.doi: 10.35541/cjd.20230354

[开放获取] 中国皮肤结核临床诊疗专家共识（2024版）

中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟
中国麻风防治协会皮肤性病检验与诊断分会

中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟
中国麻风防治协会皮肤性病检验与诊断分会

收稿日期:2023-06-19 修回日期:2024-02-04 发布日期:2024-04-30
通讯作者: 王洪生 E-mail:whs33@vip.sina.com
基金资助:
国家重点研发计划项目（2019YFE0113300）；国家自然科学基金（81972950、82173431、82103748、82203940）；江苏省医学重点实验室、江苏省科教能力提升工程项目（ZDXYS202204）

Expert consensus on the clinical diagnosis and treatment of cutaneous tuberculosis in China （2024）

Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance; Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy

Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance; Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy

Received:2023-06-19 Revised:2024-02-04 Published:2024-04-30
Contact: Wang Hongsheng E-mail:whs33@vip.sina.com
Supported by:
National Key Research and Development Program of China （2019YFE0113300）; National Natural Science Foundation of China （81972950, 82173431, 82103748, 82203940）; Jiangsu Provincial Medical Key Laboratory, Jiangsu Province Capability Improvement Project through Science, Technology and Education （ZDXYS202204）

摘要/Abstract

摘要： 【摘要】皮肤结核是由结核分枝杆菌复合群引起的慢性感染性皮肤病，临床表现多样，诊断困难，延误诊断可能导致皮肤与软组织损毁，其诊断需要综合临床、病理、实验室检查等指标综合判断。皮肤结核治疗疗程长且需要多种抗生素联合治疗，早期规范的诊疗是保证良好预后的关键。本共识在参考国内外皮肤结核与结核相关文献、指南基础上编写，旨在规范皮肤结核诊疗流程，提高皮肤结核的治疗效果。

关键词: 结核, 结核, 皮肤, 分枝杆菌, 结核, 诊断, 治疗, 专家共识

Abstract: 【Abstract】 Cutaneous tuberculosis is a chronic infectious skin disease caused by Mycobacterium tuberculosis complex. It has various clinical manifestations and is difficult to be accurately diagnosed. Delayed diagnosis may lead to serious damage to the skin and soft tissues. The diagnosis of cutaneous tuberculosis requires a comprehensive assessment of clinical, pathological, and laboratory findings. A long‐course combination antibiotic therapy is commonly needed for the treatment of cutaneous tuberculosis, and early standardized diagnosis and treatment are the key to ensuring a good prognosis. This expert consensus was developed based on Chinese and international literature and guidelines on cutaneous tuberculosis and tuberculosis, aiming to standardize the diagnostic procedure and improve the treatment outcomes of cutaneous tuberculosis.

Key words: Tuberculosis, Tuberculosis, cutaneous, Mycobacterium tuberculosis, Diagnosis, Therapy, Expert consensus

中图分类号:

中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟中国麻风防治协会皮肤性病检验与诊断分会. [开放获取] 中国皮肤结核临床诊疗专家共识（2024版）[J]. 中华皮肤科杂志, 2024,57(5):426-434. doi:10.35541/cjd.20230354

Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance, Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy. Expert consensus on the clinical diagnosis and treatment of cutaneous tuberculosis in China （2024）[J]. Chinese Journal of Dermatology, 2024, 57(5): 426-434.doi:10.35541/cjd.20230354

参考文献 77

［1］	BayBay H, Senhaji I, Zinoun S, et al. Cutaneous tuberculosis in children from the northeastern region of Morocco［J］. Arch Pediatr, 2021,28（6）:491⁃495. doi: 10.1016/j.arcped.2021.04. 011.
［2］	Sethuraman G, Ramesh V. Cutaneous tuberculosis in children［J］. Pediatr Dermatol, 2013,30（1）:7⁃16. doi: 10.1111/j.1525⁃1470.2012.01794.x.
［3］	Zawirska A, Adamski Z, Stawicka E, et al. Cutaneous squamous cell carcinoma developing in lupus vulgaris exfoliativus persistent for 40 years［J］. Int J Dermatol, 2009,48（2）:125⁃127. doi: 10.1111/j.1365⁃4632.2009.03850.x.
［4］	World Health Organization. Global tuberculosis report 2022［R/OL］. Geneva: World Health Organization, 2022［2023⁃06⁃18］. https://iris.who.int/bitstream/handle/10665/363752/9789240061729⁃eng.pdf?sequence=1.
［5］	Kozińska M, Augustynowicz⁃Kopeć E, Gamian A, et al. Cutaneous and pulmonary tuberculosis⁃diagnostic and therapeutic difficulties in a patient with autoimmunity［J］. Pathogens, 2023,12（2）:331. doi: 10.3390/pathogens12020331.
［6］	Kivanç⁃Altunay I, Baysal Z, Ekmekçi TR, et al. Incidence of cutaneous tuberculosis in patients with organ tuberculosis［J］. Int J Dermatol, 2003,42（3）:197⁃200. doi: 10.1046/j.1365⁃4362.2003.01762.x.
［7］	Santos JB, Figueiredo AR, Ferraz CE, et al. Cutaneous tuberculosis: epidemiologic, etiopathogenic and clinical aspects ⁃ part I［J］. An Bras Dermatol, 2014,89（2）:219⁃228. doi: 10.1590/abd1806⁃4841.20142334.
［8］	Jiang H, Jin Y, Vissa V, et al. Molecular characteristics of Mycobacterium tuberculosis strains isolated from cutaneous tuberculosis patients in China［J］. Acta Derm Venereol, 2017,97（4）:472⁃477. doi: 10.2340/00015555⁃2577.
［9］	Mei YM, Zhang WY, Sun JY, et al. Genomic characteristics of Mycobacterium tuberculosis isolates of cutaneous tuberculosis［J］. Front Microbiol, 2023,14:1165916. doi: 10.3389/fmicb.2023. 1165916.
［10］	Rahlwes KC, Dias B, Campos PC, et al. Pathogenicity and virulence of Mycobacterium tuberculosis［J］. Virulence, 2023,14（1）:2150449. doi: 10.1080/21505594.2022.2150449.
［11］	Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosis infections［J］. Microbiol Spectr, 2019,7（4）:10.1128/microbiolspec. GPP3⁃0022⁃2018. doi: 10.1128/microbiolspec.GPP3⁃0022⁃2018.
［12］	Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium tuberculosis［J］. Nat Rev Microbiol, 2022,20（12）:750⁃766. doi: 10.1038/s41579⁃022⁃00763⁃4.
［13］	Flynn JL, Chan J. Immune cell interactions in tuberculosis［J］. Cell, 2022,185（25）:4682⁃4702. doi: 10.1016/j.cell.2022.10.025.
［14］	Griffiths CEM, Barker J, Bleiker TO, et al. Rook′s textbook of dermatology［M］. New Jersey: Wiley⁃Blackwell, 2016.
［15］	Hill MK, Sanders CV. Cutaneous tuberculosis［J］. Microbiol Spectr, 2017,5（1）:10.1128/microbiolspec.TNMI7⁃0010⁃2016. doi: 10.1128/microbiolspec.TNMI7⁃0010⁃2016.
［16］	Beyt BE Jr, Ortbals DW, Santa Cruz DJ, et al. Cutaneous mycobacteriosis: analysis of 34 cases with a new classification of the disease［J］. Medicine （Baltimore）, 1981,60（2）:95⁃109.
［17］	Bravo FG, Gotuzzo E. Cutaneous tuberculosis［J］. Clin Dermatol, 2007,25（2）:173⁃180. doi: 10.1016/j.clindermatol.2006.05.005.
［18］	Santos JB, Figueiredo AR, Ferraz CE, et al. Cutaneous tuberculosis: diagnosis, histopathology and treatment ⁃ partⅡ［J］. An Bras Dermatol, 2014,89（4）:545⁃555. doi: 10.1590/abd1806⁃4841.20142747.
［19］	Zhang J, Fan YK, Wang P, et al. Cutaneous tuberculosis in China ⁃ a multicentre retrospective study of cases diagnosed between 1957 and 2013［J］. J Eur Acad Dermatol Venereol, 2018,32（4）:632⁃638. doi: 10.1111/jdv.14851.
［20］	Pandhi D, Reddy BS, Chowdhary S, et al. Cutaneous tuberculosis in Indian children: the importance of screening for involvement of internal organs［J］. J Eur Acad Dermatol Venereol, 2004,18（5）:546⁃551. doi: 10.1111/j.1468⁃3083.2004.00970.x.
［21］	Kumar B, Rai R, Kaur I, et al. Childhood cutaneous tuberculosis: a study over 25 years from northern India［J］. Int J Dermatol, 2001,40（1）:26⁃32. doi: 10.1046/j.1365⁃4362.2001. 01165.x.
［22］	Mann D, Sant′Anna FM, Schmaltz C, et al. Cutaneous tuberculosis and HIV infection at a referral centre in Rio de Janeiro, Brazil［J］. Mem Inst Oswaldo Cruz, 2018,113（9）:e180184. doi: 10.1590/0074⁃02760180184.
［23］	Ben Jazia E, Hachfi W, Trimech M, et al. Detection of mycobacterial tuberculosis DNA in lichen scrofulosorum［J］. J Am Acad Dermatol, 2006,55（2 Suppl）:S54⁃55. doi: 10.1016/j.jaad.2005.08.048.
［24］	Chuang YH, Kuo TT, Wang CM, et al. Simultaneous occurrence of papulonecrotic tuberculide and erythema induratum and the identification of Mycobacterium tuberculosis DNA by polymerase chain reaction［J］. Br J Dermatol, 1997,137（2）:276⁃281. doi: 10.1046/j.1365⁃2133.1997.18201916.x.
［25］	Vieites B, Suárez⁃Peñaranda JM, Pérez Del Molino ML, et al. Recovery of Mycobacterium tuberculosis DNA in biopsies of erythema induratum⁃⁃results in a series of patients using an improved polymerase chain reaction technique［J］. Br J Dermatol, 2005,152（6）:1394⁃1396. doi: 10.1111/j.1365⁃2133. 2005.06650.x.
［26］	Kaul S, Jakhar D, Mehta S, et al. Cutaneous tuberculosis. PartⅡ: complications, diagnostic workup, histopathologic features, and treatment［J］. J Am Acad Dermatol, 2023,89（6）:1107⁃1119. doi: 10.1016/j.jaad.2021.12.064.
［27］	Barbagallo J, Tager P, Ingleton R, et al. Cutaneous tuberculosis: diagnosis and treatment［J］. Am J Clin Dermatol, 2002,3（5）:319⁃328. doi: 10.2165/00128071⁃200203050⁃00004.
［28］	Sharma S, Sehgal VN, Bhattacharya SN, et al. Clinicopathologic spectrum of cutaneous tuberculosis: a retrospective analysis of 165 Indians［J］. Am J Dermatopathol, 2015,37（6）:444⁃450. doi: 10.1097/DAD.0000000000000297.
［29］	Brito AC, Oliveira C, Unger DA, et al. Cutaneous tuberculosis: epidemiological, clinical, diagnostic and therapeutic update［J］. An Bras Dermatol, 2022,97（2）:129⁃144. doi: 10.1016/j.abd.2021. 07.004.
［30］	Kathuria P, Agarwal K, Koranne RV. The role of fine⁃needle aspiration cytology and Ziehl Neelsen staining in the diagnosis of cutaneous tuberculosis［J］. Diagn Cytopathol, 2006,34（12）:826⁃9. doi: 10.1002/dc.20534.
［31］	Rademaker M, Lowe DG, Munro DD. Erythema induratum （Bazin's disease）［J］. J Am Acad Dermatol, 1989,21（4 Pt 1）:740⁃5. doi: 10.1016/s0190⁃9622（89）70248⁃6.
［32］	Tirumalae R, Yeliur IK, Antony M, et al. Papulonecrotic tuberculid⁃clinicopathologic and molecular features of 12 Indian patients［J］. Dermatol Pract Concept, 2014,4（2）:17⁃22. doi: 10. 5826/dpc.0402a03.
［33］	何翼君, 张浩然, 辛赫男, 等. 结核菌素皮肤试验的应用及其优化［J］. 中国防痨杂志, 2021,43（3）:204⁃210. doi: 10.3969/j.issn.1000⁃6621.2021.03.003.
［34］	都伟欣, 赵爱华, 王国治, 等. 结核菌素类产品的发展历程概述［J］. 中国防痨杂志, 2019,41（10）:1080⁃1083. doi: 10.3969/j.issn.1000⁃6621.2019.10.003.
［35］	Ramam M, Malhotra A, Tejasvi T, et al. How useful is the Mantoux test in the diagnosis of doubtful cases of cutaneous tuberculosis?［J］. Int J Dermatol, 2011,50（11）:1379⁃1382. doi: 10.1111/j.1365⁃4632.2011.04971.x.
［36］	Ramesh V, Gupta J. Cutaneous tuberculosis of the pinna［J］. Int J Dermatol, 2021,60（3）:363⁃367. doi: 10.1111/ijd.15249.
［37］	Nayak S, Acharjya B. Mantoux test and its interpretation［J］. Indian Dermatol Online J, 2012,3（1）:2⁃6. doi: 10.4103/2229⁃5178.93479.
［38］	Zhou G, Luo Q, Luo S, et al.Interferon⁃γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta⁃analysis ［J］. Lancet Infect Dis, 2020,20（12）:1457⁃1469. doi: 10.1016/S1473⁃3099（20）30276⁃0.
［39］	Santin M, García⁃García JM, Domínguez J, et al. Guidelines for the use of interferon⁃γ release assays in the diagnosis of tuberculosis infection［J］. Enferm Infecc Microbiol Clin, 2016,34（5）:303.e1⁃13. doi: 10.1016/j.eimc.2015.11.022.
［40］	Chen Y, Jiang H, Zhang W, et al. Diagnostic value of T⁃SPOT.TB test in cutaneous mycobacterial infections［J］. Acta Derm Venereol, 2018,98（10）:989⁃990. doi: 10.2340/00015555⁃3011.
［41］	Tebruegge M, Connell T, Ritz N, et al. Discordance between TSTs and IFN⁃gamma release assays: the role of NTM and the relevance of mycobacterial sensitins［J］. Eur Respir J, 2010,36（1）:214⁃215; author reply 215⁃216. doi: 10.1183/09031936. 00025510.
［42］	Siegel S, Cavanaugh M, Ku JH, et al. Specificity of QuantiFERON⁃TB Plus, a new⁃generation interferon gamma release assay［J］. J Clin Microbiol, 2018,56（12）:e00629⁃18. doi: 10.1128/JCM.00629⁃18.
［43］	Pan L, Jia H, Liu F, et al. Risk factors for false⁃negative T⁃SPOT.TB assay results in patients with pulmonary and extra⁃pulmonary TB［J］. J Infect, 2015,70（4）:367⁃380. doi: 10.1016/j.jinf.2014.12.018.
［44］	中华人民共和国国家卫生和计划生育委员会. 肺结核诊断标准（WS 288⁃2017）［J］. 新发传染病电子杂志, 2018,3（1）:59⁃61. doi: 10.3877/j.issn.2096⁃2738.2018.01.017.
［45］	Almaguer⁃Chávez J, Ocampo⁃Candiani J, Rendón A. Current panorama in the diagnosis of cutaneous tuberculosis［J］. Actas Dermosifiliogr, 2009,100（7）:562⁃570.
［46］	Pfyffer GE, Wittwer F. Incubation time of mycobacterial cultures: how long is long enough to issue a final negative report to the clinician?［J］. J Clin Microbiol, 2012,50（12）:4188⁃4189. doi: 10.1128/JCM.02283⁃12.
［47］	Dong B, He Z, Li Y, et al. Improved conventional and new approaches in the diagnosis of tuberculosis［J］. Front Microbiol, 2022,13:924410. doi: 10.3389/fmicb.2022.924410.
［48］	Said HM, Kock MM, Ismail NA, et al. Comparison between the BACTEC MGIT 960 system and the agar proportion method for susceptibility testing of multidrug resistant tuberculosis strains in a high burden setting of South Africa［J］. BMC Infect Dis, 2012,12:369. doi: 10.1186/1471⁃2334⁃12⁃369.
［49］	Kassaza K, Orikiriza P, Llosa A, et al. Lowenstein⁃Jensen selective medium for reducing contamination in Mycobacterium tuberculosis culture［J］. J Clin Microbiol, 2014,52（7）:2671⁃2673. doi: 10.1128/JCM.00749⁃14.
［50］	Butler WR, Guthertz LS. Mycolic acid analysis by high⁃performance liquid chromatography for identification of Mycobacterium species［J］. Clin Microbiol Rev, 2001,14（4）:704⁃726, table of contents. doi: 10.1128/CMR.14.4.704⁃726.2001.
［51］	Wu X, Tan G, Yang J, et al. Prediction of Mycobacterium tuberculosis drug resistance by nucleotide MALDI⁃TOF⁃MS［J］. Int J Infect Dis, 2022,121:47⁃54. doi: 10.1016/j.ijid.2022.04. 061.
［52］	Robinne S, Saad J, Morsli M, et al. Rapid identification of Mycobacterium tuberculosis complex using mass spectrometry: a proof of concept［J］. Front Microbiol, 2022,13:753969. doi: 10.3389/fmicb.2022.753969.
［53］	Gholoobi A, Masoudi⁃Kazemabad A, Meshkat M, et al. Comparison of culture and PCR methods for diagnosis of Mycobacterium tuberculosis in different clinical specimens［J］. Jundishapur J Microbiol, 2014,7（2）:e8939. doi: 10.5812/jjm. 8939.
［54］	Tan SH, Tan BH, Goh CL, et al. Detection of Mycobacterium tuberculosis DNA using polymerase chain reaction in cutaneous tuberculosis and tuberculids［J］. Int J Dermatol, 1999,38（2）:122⁃127. doi: 10.1046/j.1365⁃4362.1999.00576.x.
［55］	Agarwal P, Singh EN, Agarwal US, et al. The role of DNA polymerase chain reaction, culture and histopathology in the diagnosis of cutaneous tuberculosis［J］. Int J Dermatol, 2017,56（11）:1119⁃1124. doi: 10.1111/ijd.13708.
［56］	严慧, 朱庆义. 聚合酶链反应鉴定结核分枝杆菌常用靶基因序列的研究进展［J］. 中华临床实验室管理电子杂志, 2016,4（3）:159⁃163. doi: 10.3877/cma.j.issn.2095⁃5820.2016.03.007.
［57］	Makeshkumar V, Madhavan R, Narayanan S. Polymerase chain reaction targeting insertion sequence for the diagnosis of extrapulmonary tuberculosis［J］. Indian J Med Res, 2014,139（1）:161⁃166.
［58］	Tan SH, Tan HH, Sun YJ, et al. Clinical utility of polymerase chain reaction in the detection of Mycobacterium tuberculosis in different types of cutaneous tuberculosis and tuberculids［J］. Ann Acad Med Singap, 2001,30（1）:3⁃10.
［59］	World Health Organization. Xpert MTB/RIF implementation manual: technical and operational ′how⁃to′; practical considerations［M/OL］. Geneva: World Health Organization, 2014［2023⁃06⁃18］. https://iris.who.int/bitstream/handle/10665/112469/9789241506700_eng.pdf?sequence=1.
［60］	Mekkaoui L, Hallin M, Mouchet F, et al. Performance of Xpert MTB/RIF Ultra for diagnosis of pulmonary and extra⁃pulmonary tuberculosis, one year of use in a multi⁃centric hospital laboratory in Brussels, Belgium［J/OL］. PLoS One, 2021,16（4）:e0249734. doi: 10.1371/journal.pone.0249734.
［61］	Denkinger CM, Schumacher SG, Boehme CC, et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta⁃analysis［J］. Eur Respir J, 2014,44（2）:435⁃446. doi:10.1183/09031936.00007814.
［62］	Lawn SD, Zumla AI. Diagnosis of extrapulmonary tuberculosis using the Xpert® MTB/RIF assay［J］. Expert Rev Anti Infect Ther, 2012,10（6）:631⁃635. doi: 10.1586/eri.12.43.
［63］	Sun W, Lu Z, Yan L. Clinical efficacy of metagenomic next⁃generation sequencing for rapid detection of Mycobacterium tuberculosis in smear⁃negative extrapulmonary specimens in a high tuberculosis burden area［J］. Int J Infect Dis, 2021,103:91⁃96. doi: 10.1016/j.ijid.2020.11.165.
［64］	Chen P, Sun W, He Y. Comparison of metagenomic next⁃generation sequencing technology, culture and GeneXpert MTB/RIF assay in the diagnosis of tuberculosis［J］. J Thorac Dis, 2020,12（8）:4014⁃4024. doi: 10.21037/jtd⁃20⁃1232.
［65］	中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 肺结核基层诊疗指南（实践版·2018）［J］. 中华全科医师杂志, 2019,18（8）:718⁃722. doi: 10.3760/cma.j.issn.1671⁃7368. 2019.08.003.
［66］	Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug⁃susceptible tuberculosis［J］. Clin Infect Dis, 2016,63（7）:e147⁃e195. doi: 10.1093/cid/ciw376.
［67］	World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment ⁃ drug⁃susceptible tuberculosis treatment［M/OL］. Geneva: World Health Organization, 2022.［2023⁃06⁃18］. https://iris.who.int/bitstream/handle/10665/353829/ 9789240048126⁃eng.pdf?sequence=1.
［68］	World Health Organization. Dose optimization of rifampicin, isoniazid, pyrazinamide and ethambutol in the treatment of drug⁃susceptible tuberculosis［EB/OL］. Geneva: World Health Organization, 2022.［2023⁃06⁃18］. https://www.who.int/docs/default⁃source/hq⁃tuberculosis/dose⁃optimization⁃concept⁃note.pdf?sfvrsn=934ab3e2_2.
［69］	中国疾病预防控制中心结核病预防控制中心. 中国结核病防治工作技术指南（2021年版）［M］. 北京: 人民卫生出版社, 2022.
［70］	Mei Y, Zhang W, Shi Y, et al. Cutaneous tuberculosis and nontuberculous mycobacterial infections at a national specialized hospital in China［J］. Acta Derm Venereol, 2019,99（11）:997⁃1003. doi: 10.2340/00015555⁃3283.
［71］	Singal A, Kaur I, Jakhar D, et al. Clinicoepidemiological characteristics of cutaneous tuberculosis in 1458 Indian patients: a retrospective analytical study from a tertiary care center［J］. Int J Dermatol, 2022,61（8）:1012⁃1022. doi: 10.1111/ijd.16267.
［72］	Ranawaka RR, Abeygunasekara PH, Perera E, et al. Clinico⁃histopathological correlation and the treatment response of 20 patients with cutaneous tuberculosis［J］. Dermatol Online J, 2010,16（8）:13.
［73］	World Health Organization. WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents［M/OL］. Geneva: World Health Organization, 2022［2023⁃06⁃18］. https://iris.who.int/bitstream/handle/10665/352522/9789240046764⁃eng.pdf?sequence=1.
［74］	中华医学会结核病学分会. 老年肺结核诊断与治疗专家共识（2023版）［J］. 中华结核和呼吸杂志, 2023,46（11）:1068⁃1084. doi: 10.3760/cma.j.cn112147⁃20230921⁃00182.
［75］	van Zyl L, du Plessis J, Viljoen J. Cutaneous tuberculosis overview and current treatment regimens［J］. Tuberculosis （Edinb）, 2015,95（6）:629⁃638. doi: 10.1016/j.tube.2014.12.006.
［76］	World Health Organization. WHO consolidated guidelines on drug⁃resistant tuberculosis treatment［M］. Geneva:World Health Organization, 2019.
［77］	中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识（2019年版）［J］. 中华结核和呼吸杂志, 2019,42（10）:733⁃749. doi: 10.3760/cma.j.issn.1001⁃0939.2019.10. 006.

[1]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 中国难治性慢性自发性荨麻疹诊治指南（2025版）[J]. 中华皮肤科杂志, 2025, 58(6): 485-496.
[2]	黄雪薇陈奇权杨显杰陈安祺王欢邓思思翟志芳王娟宋志强. 荨麻疹性血管炎与伴色素沉着慢性自发性荨麻疹的临床与病理特征对比分析[J]. 中华皮肤科杂志, 2025, 58(6): 508-514.
[3]	邱里肖汀. 布鲁顿酪氨酸激酶抑制剂在慢性自发性荨麻疹治疗中的进展[J]. 中华皮肤科杂志, 2025, 58(6): 563-567.
[4]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 遗传性血管性水肿诊疗路径皮肤科专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(6): 497-502.
[5]	于金蕾吴桥芳孙悦鑫包军周映. 佩索利单抗治疗6例泛发性脓疱型银屑病临床观察[J]. 中华皮肤科杂志, 2025, 0(5): 20240440-e20240440.
[6]	白璐楚妍刘园园朱才勇. 慢性手部湿疹的治疗进展[J]. 中华皮肤科杂志, 2025, 58(5): 477-480.
[7]	黄和金李馨雅席文文肖霞蒋斌杨锋. 微创旋切术治疗腋臭患者3 000例术后并发症回顾分析[J]. 中华皮肤科杂志, 2025, 0(5): 20230291-e0230291.
[8]	王媛李锁李志量荆可孙超梁桂熔张寒梅冯素英. 联合血清学诊断方法在抗BP180型和抗层粘连蛋白332型黏膜类天疱疮中的临床应用[J]. 中华皮肤科杂志, 2025, 58(5): 446-452.
[9]	杜雅馨笪美红胡雅坤吴雯婕陶咪严翘董正邦王飞. 无针注射干扰素α2a治疗掌跖疣的疗效与安全性：一项前瞻性、随机、对照、开放标签试验[J]. 中华皮肤科杂志, 2025, 58(5): 440-445.
[10]	孙雨欣霍思懿陈佳妤熊和平朱明芳. 新型冠状病毒感染相关皮肤病：长沙地区一项横断面调查[J]. 中华皮肤科杂志, 2025, 58(5): 464-469.
[11]	邓维蒋丽潇苏伟杨宙刘晓雁张高磊. 肺炎支原体诱发的皮疹和黏膜炎患儿15例临床表现分析[J]. 中华皮肤科杂志, 2025, 58(5): 460-463.
[12]	中国儿童鲜红斑痣诊断和治疗专家共识制订专家组中国医师协会皮肤科医师分会儿童学组. [开放获取] 儿童鲜红斑痣诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 396-404.
[13]	中国医师协会皮肤科医师分会中华医学会皮肤病学分会治疗学组中国医疗保健国际交流促进会皮肤医学分会国家皮肤与免疫疾病临床医学研究中心中国罕见病联盟皮肤罕见病专业委员会. 大疱性类天疱疮诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 405-415.
[14]	中国中西医结合学会皮肤性病专业委员会皮肤肿瘤学组中国抗癌协会黑色素瘤专业委员会中国抗癌协会皮肤肿瘤整合康复专业委员会. [开放获取] 色素痣诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 387-395.
[15]	中华医学会皮肤性病学分会儿童学组中华医学会儿科学分会皮肤性病学组中国康复医学会皮肤病康复专业委员会中国医师协会皮肤科医师分会儿童皮肤病学组. [开放获取] 中国儿童特应性皮炎专病门诊建设及标准化病案管理专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 0(4): 20240338-e20240338.

[开放获取] 中国皮肤结核临床诊疗专家共识（2024版）

Expert consensus on the clinical diagnosis and treatment of cutaneous tuberculosis in China （2024）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 77

相关文章 15

Metrics

本文评价

推荐阅读 10